We are live on ! Find out more
ACIU icon

AC Immune

45 hedge funds and large institutions have $73.9M invested in AC Immune in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,957% more call options, than puts

Call options by funds: $144K | Put options by funds: $7K

5% more funds holding

Funds holding: 43 → 45 (+2)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

0.83% less ownership

Funds ownership: 28.29% → 27.46% (-0.83%)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

68% less capital inflows, than outflows

Capital inflows: $1.96M | Capital outflows: $6.07M

Holders
45
Holders Change
+2
Holders Change %
+4.65%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
13
Closed
8
Calls
$144​K
Puts
$7​K
Net Calls
+$137​K
Net Calls Change
-⁠$409​K

ACIU Hedge Fund Activity: Q4 2024 in Review

45 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q4 2024, worth a combined $73.9M — down 31% from $107M a quarter earlier.

Fund positioning in ACIU was balanced in Q4 2024: 8 funds opened new positions, 8 closed out, 12 added to existing stakes and 13 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $476K. The largest seller was Redmile Group, cutting an estimated $2.06M.

  • 45 institutional investors held AC Immune (ACIU) as of Q4 2024, up from 43 in Q3 2024.
  • Funds reported $73.9M of AC Immune stock for Q4 2024, down 31% quarter-over-quarter.
  • 8 funds opened new AC Immune positions in Q4 2024 and 8 closed out, a net change of 0 holders.
  • The largest AC Immune buyer in Q4 2024 was Acadian Asset Management, an estimated $476K added.
  • The largest AC Immune seller in Q4 2024 was Redmile Group, an estimated $2.06M sold.

Based on aggregated 13F filings for Q4 2024.